With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?

The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.

By Meagan Parrish • Oct. 3, 2025

Takeda, in reversal, abandons cell therapy research

The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.

By Delilah Alvarado • Oct. 2, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

Top pharma industry conferences remaining in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in the second half of 2026.

By Meagan Parrish • Updated June 29, 2026

AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

The new treatment may only offer modest benefits, but could gain traction in a market with few other options.

By Kelly Bilodeau • Sept. 30, 2025

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

By Michael Gibney • Sept. 25, 2025

Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.

By Gwendolyn Wu • Sept. 25, 2025

Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach

Why multi-specific antibodies are seeing a fresh surge of industry buzz.

By Kelly Bilodeau • Sept. 24, 2025

Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

By Michael Gibney • Sept. 23, 2025

3 FDA approval firsts that could be around the corner

Several market-altering decisions are on the agency’s docket for the rest of 2025.

By Meagan Parrish • Sept. 19, 2025

How pharma can play a role in the $1 trillion healthcare reinvention

A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.

By Michael Gibney • Sept. 18, 2025

AI agents are coming to pharma. Here’s what it means for clinical trials.

The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

By Kelly Bilodeau • Sept. 17, 2025

Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’

Amid the sector’s long winter, startups are shifting gears to extend their cash runways.

By Michael Gibney • Sept. 17, 2025

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

By Kelly Bilodeau • Sept. 15, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 10, 2025

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.

By Alexandra Pecci • Sept. 10, 2025

Can new Alzheimer’s tests help clear the way for the next generation of therapies?

A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.

By Michael Gibney • Sept. 9, 2025

Inside pharma’s race to deliver new treatments for dwarfism

By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.

By Kelly Bilodeau • Sept. 8, 2025

International appeal: Europe and UK lure US scientists with financial incentives

With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.

By Alexandra Pecci • Sept. 4, 2025

How AI advances will shape the drugmaker of the future

An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

By Michael Gibney • Sept. 2, 2025

How a SpaceX mission could speed drug discoveries on Earth

Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.

By Kelly Bilodeau • Aug. 28, 2025